ERBB2 and breast adenocarcinoma: A human neoplastic cell type other than chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) could have been applied to access anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-EGFR] in dual simultaneous combination with gemcitabine-(C4-amide)-[anti-HER2/neu].